159837 生物科技
已收盘 02-13 15:00:00
资讯
新帖
简况
2026年中国生物科技授权交易将迎爆发式增长,有望创历史新高
环球市场播报 · 02-13 17:52
2026年中国生物科技授权交易将迎爆发式增长,有望创历史新高
四方光电:2026年1月,公司以自有资金受让出资额并增资的方式取得苏州畅合生物科技有限公司57.14%的股权
证券日报 · 02-12 21:38
四方光电:2026年1月,公司以自有资金受让出资额并增资的方式取得苏州畅合生物科技有限公司57.14%的股权
百龙创园(605016.SH)拟设立百龙创园(南京)生物科技有限公司
智通财经 · 02-11
百龙创园(605016.SH)拟设立百龙创园(南京)生物科技有限公司
华润医药(03320)潜在出售天麦生物科技约17.87 %股权
智通财经 · 02-09
华润医药(03320)潜在出售天麦生物科技约17.87 %股权
山西山阴生物科技公司爆炸已致8人遇难,涉事企业法人代表已被控制
新京报网 · 02-08
山西山阴生物科技公司爆炸已致8人遇难,涉事企业法人代表已被控制
山东新华制药股份(00719)终止收购挪亚圣诺(太仓)生物科技有限公司股权
智通财经 · 02-06
山东新华制药股份(00719)终止收购挪亚圣诺(太仓)生物科技有限公司股权
新华医疗最新公告:终止收购武汉中帜生物科技股份有限公司36.19%股权
证券之星 · 02-06
新华医疗最新公告:终止收购武汉中帜生物科技股份有限公司36.19%股权
爱普股份(603020.SH)签订关于挪亚圣诺(太仓)生物科技有限公司股权收购意向协议
智通财经 · 02-06
爱普股份(603020.SH)签订关于挪亚圣诺(太仓)生物科技有限公司股权收购意向协议
温氏股份最新公告:拟与专业投资机构及关联方共同投资山东恒鑫生物科技
证券之星 · 02-05
温氏股份最新公告:拟与专业投资机构及关联方共同投资山东恒鑫生物科技
AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床
智通财经网 · 02-05
AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床
诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心
澎湃新闻 · 02-05
诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心
生物科技公司PrimeGen将通过15亿美元SPAC交易上市
环球市场播报 · 02-04
生物科技公司PrimeGen将通过15亿美元SPAC交易上市
恒指公司:2025年港股科技与生物科技主题表现突出 恒生双科技指数创下自推出以来最佳表现
智通财经 · 02-04
恒指公司:2025年港股科技与生物科技主题表现突出 恒生双科技指数创下自推出以来最佳表现
怡达股份最新公告:控股子公司泰兴怡达吸收合并其全资子公司万淇生物科技
证券之星 · 02-03
怡达股份最新公告:控股子公司泰兴怡达吸收合并其全资子公司万淇生物科技
慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股 拟募资1.5亿美元
智通财经 · 01-30
慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股 拟募资1.5亿美元
逆势溢价近40%募资超7亿,觅瑞如何成为港股生物科技“价值标杆”?
21世纪经济报道 · 01-30
逆势溢价近40%募资超7亿,觅瑞如何成为港股生物科技“价值标杆”?
比利时免疫炎症生物科技公司AgomAb Therapeutics(AGMB.US)申请在美IPO 拟募资1亿美元
智通财经 · 01-19
比利时免疫炎症生物科技公司AgomAb Therapeutics(AGMB.US)申请在美IPO 拟募资1亿美元
上海多宁生物科技股份有限公司向港交所提交上市申请书
每日经济新闻 · 01-18
上海多宁生物科技股份有限公司向港交所提交上市申请书
康希诺:公司不持有磐如生物科技(天津)有限公司的股份
证券日报 · 01-13
康希诺:公司不持有磐如生物科技(天津)有限公司的股份
生物科技公司Alveus融资1.6亿美元,专攻减重维持难题
环球市场播报 · 01-08
生物科技公司Alveus融资1.6亿美元,专攻减重维持难题
加载更多
公司概况
公司名称:
--
所属市场:
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"159837","market":"SZ","secType":"STK","nameCN":"生物科技","latestPrice":0.501,"timestamp":1770966216000,"preClose":0.508,"halted":0,"volume":36249202,"delay":0,"changeRate":-0.0138,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.007,"latestTime":"02-13 15:00:00","open":0.507,"high":0.509,"low":0.501,"amount":18295000,"amplitude":0.0157,"askPrice":0.502,"askSize":4164,"bidPrice":0.501,"bidSize":4970,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771896600000},"marketStatusCode":5,"adr":0,"adjPreClose":0.508,"symbolType":"fund","openAndCloseTimeList":[[1770946200000,1770953400000],[1770958800000,1770966000000]],"highLimit":0.559,"lowLimit":0.457,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.060194,"marketValue":0,"turnoverRate":0,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-02-24。","floatMarketCap":0},"requestUrl":"/m/hq/s/159837","defaultTab":"news","newsList":[{"id":"2611130059","title":"2026年中国生物科技授权交易将迎爆发式增长,有望创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2611130059","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611130059?lang=zh_cn&edition=full","pubTime":"2026-02-13 17:52","pubTimestamp":1770976320,"startTime":"0","endTime":"0","summary":"全球制药企业在专利到期前纷纷削减成本,正加大力度寻找中国研发的创新候选药物,行业分析师预计,今年相关授权交易规模将飙升至历史新高。 中国大陆是这一浪潮的绝对核心。 “未来 18–24 个月,这类对外授权交易总额有望再翻一番。全球药企正高度聚焦在中国寻找下一代创新药管线,并探索多种交易结构。” 2026 年至今已宣布38 笔对外授权交易;2025 年全年为186 笔。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-13/doc-inhmskfk5919270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837","BK4588","BK4585","LABU"],"gpt_icon":0},{"id":"2610692400","title":"四方光电:2026年1月,公司以自有资金受让出资额并增资的方式取得苏州畅合生物科技有限公司57.14%的股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2610692400","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610692400?lang=zh_cn&edition=full","pubTime":"2026-02-12 21:38","pubTimestamp":1770903480,"startTime":"0","endTime":"0","summary":"证券日报网2月12日讯 ,四方光电在接受调研者提问时表示,2026年1月,公司以自有资金受让出资额并增资的方式取得苏州畅合生物科技有限公司57.14%的股权。本次投资是基于公司战略发展规划所作出的审慎决策,旨在拓展公司在生物安全监测领域的业务布局。此次战略整合畅合生物,双方将在产品技术开发、运营生产和销售渠道等方面深度融合,将四方光电的传感器产业领域向更加高端的生物安全检测仪器领域拓展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-12/doc-inhmqmpz6698250.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-12/doc-inhmqmpz6698250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0214","159837","BK4585","LABU","688665","BK4588"],"gpt_icon":0},{"id":"2610780989","title":"百龙创园(605016.SH)拟设立百龙创园(南京)生物科技有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2610780989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610780989?lang=zh_cn&edition=full","pubTime":"2026-02-11 15:40","pubTimestamp":1770795623,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百龙创园(605016.SH)发布公告,公司基于发展战略规划及经营发展需要,以自有资金1000万元,在南京投资设立全资子公司百龙创园(南京)生物科技有限公司(简称“南京百龙”),公司直接持有南京百龙100%的股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0226","605016","159837","LABU","BK4588","BK4585"],"gpt_icon":0},{"id":"2610321176","title":"华润医药(03320)潜在出售天麦生物科技约17.87 %股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2610321176","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610321176?lang=zh_cn&edition=full","pubTime":"2026-02-09 19:47","pubTimestamp":1770637624,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华润医药(03320)发布公告,本公司全资附属公司华润医药投资有限公司(华润医药投资)已启动潜在出售华润医药投资及其附属公司所持有合肥天麦生物科技发展有限公司(天麦生物科技)的约17.87 %股权(潜在出售事项),其将通过上海联合产权交易所进行公开挂牌,挂牌底价约为人民币14.2亿元。于本公告日期,华润医药投资及其附属公司持有天麦生物科技少于30 %股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","BK1570","BK1191","LABU","03320","159837"],"gpt_icon":0},{"id":"2609522115","title":"山西山阴生物科技公司爆炸已致8人遇难,涉事企业法人代表已被控制","url":"https://stock-news.laohu8.com/highlight/detail?id=2609522115","media":"新京报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609522115?lang=zh_cn&edition=full","pubTime":"2026-02-08 10:03","pubTimestamp":1770516180,"startTime":"0","endTime":"0","summary":"据新华社太原2月8日电 记者8日9时30分左右从山西省朔州市山阴县佳鹏生物科技有限公司“2·07”事故现场指挥部了解到,2月7日凌晨在山阴县佳鹏生物科技有限公司发生的爆炸已造成8人遇难。目前,涉事企业法人代表已被控制,朔州市已经成立事故调查组。事发企业位于距离山阴县城40余公里的一处山洼中,记者在事故现场看到,事发地有暗黄色烟雾散出,现场处置工作仍在进行。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-02-08/doc-inhmaism3364455.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-08/doc-inhmaism3364455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837","LABU","BK4588","BK4585"],"gpt_icon":0},{"id":"2609569452","title":"山东新华制药股份(00719)终止收购挪亚圣诺(太仓)生物科技有限公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2609569452","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609569452?lang=zh_cn&edition=full","pubTime":"2026-02-06 17:50","pubTimestamp":1770371401,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,有关本公司与挪亚圣诺(欧洲)公司签署《股权收购意向协议》。股权收购意向协议仅系各方经友好协商达成的初步意向,然而,经进一步讨论及磋商后,订约方未能就正式协议的条款及条件达成共识。本公司因此并无就该项目订立正式协议,该项目亦不会进行。故此,本公司已决定终止该等股权收购意向协议。终止《股权收购意向协议》系本公司审慎研究后作出的决定,不会影响本公司现有生产经营活动,也不会对本公司的发展造成不利影响,不存在损害本公司及全体股东,特别是中小股东利益的情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","LABU","BK4585","159837","00719","BK4588"],"gpt_icon":0},{"id":"2609631135","title":"新华医疗最新公告:终止收购武汉中帜生物科技股份有限公司36.19%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2609631135","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609631135?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:36","pubTimestamp":1770366978,"startTime":"0","endTime":"0","summary":"新华医疗(600587.SH)公告称,公司与交易各方友好协商,决定终止收购武汉中帜生物科技股份有限公司36.1913%股权的事项。由于《股份转让协议》约定的交割期限已过,且付款先决条件未达成,公司未支付任何款项,因此不存在违约情形。本次收购的终止不会对公司现有经营业绩及财务状况产生不利影响。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600027090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0251","600587","159837","BK0028"],"gpt_icon":0},{"id":"2609884375","title":"爱普股份(603020.SH)签订关于挪亚圣诺(太仓)生物科技有限公司股权收购意向协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2609884375","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609884375?lang=zh_cn&edition=full","pubTime":"2026-02-06 01:34","pubTimestamp":1770312881,"startTime":"0","endTime":"0","summary":"智通财经APP讯,爱普股份 发布公告,为完善公司战略布局,推动产业链的补强与延伸,实现公司高质量发展,2026年2月4日,公司与挪亚圣诺欧洲签订了《关于挪亚圣诺(太仓)生物科技有限公司之股权收购意向协议》,爱普股份拟受让挪亚圣诺(太仓)生物科技有限公司100% 股权,其中:首次交易即爱普股份受让目标公司80%股权,第二次交易于业绩承诺期满后启动,爱普股份将受让目标公司剩余股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0226","BK4588","BK4585","603020","LABU","159837"],"gpt_icon":0},{"id":"2609376473","title":"温氏股份最新公告:拟与专业投资机构及关联方共同投资山东恒鑫生物科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2609376473","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609376473?lang=zh_cn&edition=full","pubTime":"2026-02-05 19:00","pubTimestamp":1770289217,"startTime":"0","endTime":"0","summary":"温氏股份(300498.SZ)公告称,公司全资子公司广东温氏投资有限公司拟与关联方温润农业生物基金、温润安享、专业投资机构滨州智空基金等共同投资山东恒鑫生物科技有限公司,温氏投资本次拟以自有资金出资不超过20,500万元。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500033031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","159837","BK0187","300498","BK0012","BK0188","BK0194","BK0195","BK0240"],"gpt_icon":0},{"id":"2609321873","title":"AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2609321873","media":"智通财经网","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609321873?lang=zh_cn&edition=full","pubTime":"2026-02-05 14:52","pubTimestamp":1770274343,"startTime":"0","endTime":"0","summary":"专注于哮喘治疗的AI生物科技公司Generate Biomedicines(GENB.US)周三向美国证券交易委员会提交文件,计划通过首次公开募股筹集至多1亿美元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["III","BK4588","BK4585","LABU","159837","BK4134"],"gpt_icon":0},{"id":"2609347749","title":"诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2609347749","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609347749?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:49","pubTimestamp":1770270542,"startTime":"0","endTime":"0","summary":"【诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心】“毫无疑问,中国不仅已经成为像诺华这样的大型制药公司极为重要的市场,同时也正在迅速成长为一个全球性的研发与生物科技中心。”2月4日,诺华(NVS.US)首席执行官万思瀚在财报会上表达了上述观点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642639990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642639990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B2B36J28.USD","BK4585","LU0208291251.USD","BK4578","BK4532","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LABU","159837","IE00BJT1NW94.SGD","LU0320765489.SGD","BK4007","LU0070302665.USD","LU0211331839.USD","BK4588","NVS","IE0002141913.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2608138360","title":"生物科技公司PrimeGen将通过15亿美元SPAC交易上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2608138360","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608138360?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:16","pubTimestamp":1770214560,"startTime":"0","endTime":"0","summary":"生物科技公司 PrimeGen US 周三表示,将通过与空白支票公司 DT Cloud Star Acquisition 达成的15 亿美元交易,在美国实现上市。 该交易预计于2026 年下半年完成。合并后的公司将以 PrimeGen US 名义运营,并计划在纳斯达克交易所挂牌上市。 此次交易落地之际,企业对通过特殊目的收购公司合并实现上市的兴趣再度升温,将其作为传统上市方式的替代选择。 PrimeGen 是一家专注于干细胞疗法研发的生物科技公司,主打针对急性肝损伤及相关重症的治疗方案。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-04/doc-inhksktz9552911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837","BK4588","BK4585","LABU"],"gpt_icon":0},{"id":"2608334457","title":"恒指公司:2025年港股科技与生物科技主题表现突出 恒生双科技指数创下自推出以来最佳表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2608334457","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608334457?lang=zh_cn&edition=full","pubTime":"2026-02-04 13:47","pubTimestamp":1770184057,"startTime":"0","endTime":"0","summary":"恒生科技指数与恒生生物科技指数均于2025年创下年度升幅纪录科技与生物科技领域在2025年受到市场高度关注,相关基准指数的卓越表现充份印证这一点。同时,恒生生物科技指数亦录得64.5%的升幅,为自2019年12月推出以来的最佳年度表现。截至2026年1月30日,恒生双科技指数共有58只成份股,具体数量会因恒生科技指数与恒生生物科技指数之间的重迭程度而有所变化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["513600","BK4585","MHImain","159837","LABU","YANG","HSI","BK4588","MCHmain","HSImain","02833","159741","BK4614","HHImain"],"gpt_icon":0},{"id":"2608826604","title":"怡达股份最新公告:控股子公司泰兴怡达吸收合并其全资子公司万淇生物科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2608826604","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608826604?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:53","pubTimestamp":1770108787,"startTime":"0","endTime":"0","summary":"怡达股份(300721.SZ)公告称,为优化管理架构,提高运营效率,其控股子公司泰兴怡达化学有限公司将吸收合并其全资子公司万淇生物科技(泰州)有限公司。吸收合并完成后,万淇的法人资格将注销,其业务、资产、负债等均由泰兴怡达承继。本次吸收合并不涉及泰兴怡达的名称、注册资本、股权结构变化,且不构成重大资产重组。该事项已通过泰兴怡达股东会决议,无需提交怡达股份董事会审议。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300028419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159837","300721","BK0229"],"gpt_icon":0},{"id":"2607009988","title":"慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股 拟募资1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607009988","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607009988?lang=zh_cn&edition=full","pubTime":"2026-01-30 14:55","pubTimestamp":1769756130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,专注慢性眼病治疗植入物研发、处于三期临床试验阶段的生物科技企业SpyGlass Pharma于周四公布其首次公开发行的发行条款。这家总部位于美国加利福尼亚州阿利索维耶霍市的企业,计划以每股15-17美元的价格发行940万股股票,募资1.5亿美元。按拟议发行价区间中值计算,SpyGlass Pharma的完全摊薄后市值将达5.49亿美元。SpyGlass Pharma成立于2019年,计划在纳斯达克挂牌上市,股票代码为“SGP”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","159837","BK4585","BK4588"],"gpt_icon":0},{"id":"2607099983","title":"逆势溢价近40%募资超7亿,觅瑞如何成为港股生物科技“价值标杆”?","url":"https://stock-news.laohu8.com/highlight/detail?id=2607099983","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607099983?lang=zh_cn&edition=full","pubTime":"2026-01-30 14:53","pubTimestamp":1769755980,"startTime":"0","endTime":"0","summary":"1月29日,香港交易所的生物医药板块出现了一例引人注目的融资事件——上市仅八个月的Mirxes觅瑞(股票代码:2629.HK)宣布完成新股配售,募集资金约7.11亿港元。更值得关注的是,此次配售定 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260130/c674430392.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260130/c674430392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"gpt_icon":0},{"id":"2604462189","title":"比利时免疫炎症生物科技公司AgomAb Therapeutics(AGMB.US)申请在美IPO 拟募资1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604462189","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604462189?lang=zh_cn&edition=full","pubTime":"2026-01-19 16:32","pubTimestamp":1768811576,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,总部位于比利时、专注于免疫及炎症性疾病领域的临床二期生物科技公司AgomAb Therapeutics,于上周五向美国证券交易委员会提交申请,计划通过首次公开募股募资最高1亿美元。据招股书介绍,AgomAb Therapeutics是一家临床阶段生物制药企业,核心业务为研发免疫及炎症性疾病领域的创新性疾病修饰疗法。此前,AgomAb Therapeutics已于2024年6月20日提交秘密招股文件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159837","LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2604973632","title":"上海多宁生物科技股份有限公司向港交所提交上市申请书","url":"https://stock-news.laohu8.com/highlight/detail?id=2604973632","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604973632?lang=zh_cn&edition=full","pubTime":"2026-01-18 19:17","pubTimestamp":1768735020,"startTime":"0","endTime":"0","summary":"每经AI快讯,1月18日,港交所文件显示,上海多宁生物科技股份有限公司向港交所提交上市申请书,联席保荐人为摩根士丹利、华泰国际。 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260118/c674103170.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260118/c674103170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"gpt_icon":0},{"id":"2603680381","title":"康希诺:公司不持有磐如生物科技(天津)有限公司的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603680381","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603680381?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:06","pubTimestamp":1768313165,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日,康希诺在互动平台回答投资者提问时表示,公司不持有磐如生物科技(天津)有限公司的股份,与其为合作关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617716055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159837","BK0239","688185"],"gpt_icon":0},{"id":"2601360679","title":"生物科技公司Alveus融资1.6亿美元,专攻减重维持难题","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360679","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601360679?lang=zh_cn&edition=full","pubTime":"2026-01-08 22:12","pubTimestamp":1767881520,"startTime":"0","endTime":"0","summary":"生物科技企业Alveus治疗公司于周四宣布,已完成 1.598 亿美元融资,这笔资金将用于研发肥胖症治疗方案,重点解决患者长期维持减重效果的难题。该公司表示,这正是现有疗法未能攻克的痛点。Alveus首席执行官拉吉坎南表示,公司的研发目标聚焦于减重效果维持、提升用药耐受性以及优化身体成分,而非简单地追求减重磅数最大化。 美国国立卫生研究院的数据显示,截至 2024 年,美国成年人的肥胖率已超过 40%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-08/doc-inhfreqi3649127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771089402427,"stockEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":-0.0807},{"period":"3month","weight":-0.0705},{"period":"6month","weight":-0.0907},{"period":"1year","weight":0.1386},{"period":"ytd","weight":0.0142}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,159837,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}